Intracoronary Injection of Autologous CD34+Cells Improves One-Year Left Ventricular Systolic Function in Patients with Diffuse Coronary Artery Disease and Preserved Cardiac Performance-A Randomized, Open-Label, Controlled Phase II Clinical Trial

doi:10.3390/jcm9041043

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24882

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24882

Title:	Intracoronary Injection of Autologous CD34+Cells Improves One-Year Left Ventricular Systolic Function in Patients with Diffuse Coronary Artery Disease and Preserved Cardiac Performance-A Randomized, Open-Label, Controlled Phase II Clinical Trial
Authors:	Sung, PH;Li, YC;Lee, MS;Hsiao, HY;Ma, MC;Pei, SN;Chiang, HJ;Lee, FY;Yip, HK
Keywords:	diffuse coronary artery disease;angiogenesis;CD34+cells;preserved LVEF;heart failure;angina;dyspnea
Date:	2020
Issue Date:	2022-08-09T08:09:31Z (UTC)
Publisher:	MDPI
Abstract:	This phase II randomized controlled trial tested whether intracoronary autologous CD34+ cell therapy could further improve left ventricular (LV) systolic function in patients with diffuse coronary artery disease (CAD) with relatively preserved LV ejection fraction (defined as LVEF >40%) unsuitable for coronary intervention. Between December 2013 and November 2017, 60 consecutive patients were randomly allocated into group 1 (CD34+ cells, 3.0 x 10(7)/vessel/n = 30) and group 2 (optimal medical therapy; n = 30). All patients were followed for one year, and preclinical and clinical parameters were compared between two groups. Three-dimensional echocardiography demonstrated no significant difference in LVEF between groups 1 and 2 (54.9% vs. 51.0%, respectively, p = 0.295) at 12 months. However, compared with baseline, 12-month LVEF was significantly increased in group 1 (p < 0.001) but not in group 2 (p = 0.297). From baseline, there were gradual increases in LVEF in group 1 compared to those in group 2 at 1-month, 3-months, 6-months and 12 months (+1.6%, +2.2%, +2.9% and +4.6% in the group 1 vs. -1.6%, -1.5%, -1.4% and -0.9% in the group 2; all p < 0.05). Additionally, one-year angiogenesis (2.8 +/- 0.9 vs. 1.3 +/- 1.1), angina (0.4 +/- 0.8 vs. 1.8 +/- 0.9) and HF (0.7 +/- 0.8 vs. 1.8 +/- 0.6) scores were significantly improved in group 1 compared to those in group 2 (all p < 0.001). In conclusion, autologous CD34+ cell therapy gradually and effectively improved LV systolic function in patients with diffuse CAD and preserved LVEF who were non-candidates for coronary intervention (Trial registration: ISRCTN26002902 on the website of ISRCTN registry).
URI:	http://dx.doi.org/10.3390/jcm9041043 https://www.webofscience.com/wos/woscc/full-record/WOS:000531821000150 https://ir.csmu.edu.tw:8080/handle/310902500/24882
Relation:	JOURNAL OF CLINICAL MEDICINE ,2020 ,v9 ,issue 4
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	154	View/Open

Loading...